OPC 64005

Drug Profile

OPC 64005

Alternative Names: OPC64005

Latest Information Update: 02 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lundbeck A/S; Otsuka America Pharmaceutical
  • Developer Otsuka America Pharmaceutical
  • Class
  • Mechanism of Action Dopamine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Major depressive disorder

Most Recent Events

  • 31 Oct 2017 Otsuka Pharmaceutical Development & Commercialization plans a phase II trial for Attention-deficit hyperactivity disorder (In adults) in USA in November 2017 (NCT03324581)
  • 01 May 2015 Phase-I clinical trials in Major depressive disorder (In volunteers) in Japan (PO) (JapicCTI152934)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top